{"SPADE_UN_19014": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_19014", "Peptide Name": "6K-WY2 (Synthetic AMPs, Temporin-WY2 analog, Lys-rich, Leu-rich, XXA, UCLL1c)", "Source": "Designed based an amphibian template", "Family": "Not found", "Gene": "Not found", "Sequence": "KKKKKKFLPFLASLALKIL", "Sequence Length": 19, "UniProt Entry": "Ref", "Protein Existence": "Not found", "Biological Activity": ["Anti-Gram+", "Anti-Gram-", "Anti-MRSA", "Hemolytic", "Antibiofilm"], "Target Organism": "Not found", "Hemolytic Activity": "Not found", "Cytotoxicity": "Not found", "Binding Target": "Not found", "Linear/Cyclic": "Not found", "N-terminal Modification": "Not found", "C-terminal Modification": "Not found", "Stereochemistry": "Not found", "Structure Description": "Not found", "Formula": "Not found", "Mass": 2214.86, "PI": 10.78, "Hydrophobicity": 0.16, "Half Life": "Not found", "Function": "Not found", "Literature": [{"Author": "Liao F, Ye Z, Cheng J, Zhu J, Chen X, Zhou X, Wang T, Jiang Y, Ma C, Zhou M, Chen T, Shaw C, Wang L. 2024", "Reference": "Sci Rep. 2024 Aug 13;14(1):18769. doi: 10.1038/s41598-024-67777-1.PubMed", "Title": "Discovery and engineering of a novel peptide, Temporin-WY2, with enhanced in vitro and in vivo efficacy against multi-drug resistant bacteria"}], "Frequent Amino Acids": "KLA", "Absent Amino Acids": "CDEGHMNOQRTUVWY", "Basic Residues": 7, "Acidic Residues": 0, "Hydrophobic Residues": 11, "Polar Residues": 10, "Positive Residues": 7, "Negative Residues": 0, "Net Charge": 7, "Comments": "Sequence analysis: APD analysis reveals that this sequence is similar (68.42%) toTemporin-WY2Leu: 26%; K: 37%; F=A: 11%.Chemical modification:  C-terminal amidated.Activity: active against Gram+ bacteria S. aureus ATCC CRM 6538 or MRSA BAA 1707 or clinical MRSA B038 V1S1 A (MIC 4-16 uM), E. faecalis NCTC 12697 (MIC 16 uM), Gram- E. coli NCTC 8739 or clinical BAA 2340 (MIC 4 uM), P. aeruginosa ATCC 9027 or PA14 or PAO1 (MIC 4-8 uM), K. pneumoniae ATCC 43816 (MIC 4 uM).Antimicrobial robustness: NaCl-insensitive:E. coli (150 mM), KCl-insensitive:E. coli (4. 5 mM), NH4Cl-insensitive:E. coli (6 uM), CaCl2-sensitive:E. coli (2.5 mM), MgCl2-insensitive:E. coli (1 mM),  ZnCl2-insensitive:E. coli (8 mM), FeCl3-insensitive:E. coli (4 uM). Salt-insensitive:E. coli. NaCl-sensitized:P. aeruginosa (150 mM), KCl-insensitive:P. aeruginosa (4. 5 mM), NH4Cl-insensitive:P. aeruginosa (6 uM), CaCl2-sensitive:P. aeruginosai (2.5 mM), MgCl2-insensitive:P. aeruginosa PA14 (1 mM),  ZnCl2-insensitive:P. aeruginosa (8 mM), FeCl3-insensitive:P. aeruginosa (4 uM). Against the PA14 strain. MgCl2-sensitive:P. aeruginosa PAO1 (1 mM).  Human serum-insensitive:MRSA (%?).Biofilms: S. aureus: Inhibited formation (MBIC 2-8 uM). Disrupt preformed biofilms: E. coli (MBEC 32 uM).Structure:  random coils in NH4AC buffer and helical in 50% TFE.In vitro toxicity: horse RBC: HC50=32 uM.", "Similar Sequences": [{"SPADE_ID": "SPADE_N_08584", "Similarity": 1.0, "Sequence": "KKKK"}, {"SPADE_ID": "SPADE_N_10106", "Similarity": 1.0, "Sequence": "FKFKKKKKKK"}, {"SPADE_ID": "SPADE_N_10107", "Similarity": 1.0, "Sequence": "GFGKGFGKKKKKK"}]}}}